SELLAS Life Sciences Group, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
7 TIMES SQUARE, NEW YORK, NY, 10036
Mailing Address
7 TIMES SQUARE, NEW YORK, NY, 10036
Phone
6462005278
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$26.86M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Advanced drug pipeline with two main candidates, GPS (AML) and GFH009 (blood/solid tumors).
- Continued patient enrollment in pivotal Phase 3 REGAL study for GPS, a critical step for potential regulatory approval.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.